1. Home
  2. PSTL vs ATYR Comparison

PSTL vs ATYR Comparison

Compare PSTL & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Postal Realty Trust Inc.

PSTL

Postal Realty Trust Inc.

HOLD

Current Price

$16.16

Market Cap

329.8M

Sector

Real Estate

ML Signal

HOLD

Logo aTyr Pharma Inc.

ATYR

aTyr Pharma Inc.

HOLD

Current Price

$0.73

Market Cap

79.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PSTL
ATYR
Founded
2018
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
329.8M
79.2M
IPO Year
2019
2015

Fundamental Metrics

Financial Performance
Metric
PSTL
ATYR
Price
$16.16
$0.73
Analyst Decision
Buy
Buy
Analyst Count
3
6
Target Price
$17.58
$8.75
AVG Volume (30 Days)
213.1K
2.2M
Earning Date
11-04-2025
11-06-2025
Dividend Yield
6.01%
N/A
EPS Growth
508.95
N/A
EPS
0.48
N/A
Revenue
$91,195,000.00
$190,000.00
Revenue This Year
$24.54
N/A
Revenue Next Year
$12.00
$18,728.88
P/E Ratio
$33.36
N/A
Revenue Growth
26.65
N/A
52 Week Low
$12.26
$0.64
52 Week High
$16.50
$7.29

Technical Indicators

Market Signals
Indicator
PSTL
ATYR
Relative Strength Index (RSI) 67.03 41.71
Support Level $15.37 $0.70
Resistance Level $16.39 $0.83
Average True Range (ATR) 0.29 0.05
MACD 0.09 0.01
Stochastic Oscillator 79.20 26.75

Price Performance

Historical Comparison
PSTL
ATYR

About PSTL Postal Realty Trust Inc.

Postal Realty Trust Inc is an internally managed real estate corporation that owns and manages properties leased to the United States Postal Service, or the USPS. Its objective is to create stockholder value by generating risk-adjusted returns through expanding its portfolio of owned and managed postal properties leased to the USPS. The majority of the revenue is generated from the rental income received.

About ATYR aTyr Pharma Inc.

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

Share on Social Networks: